Evidence map›Paper›PMID 30953468›Full record

ArticleBMC cancer2019

Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor.

Olga M Koper-Lenkiewicz, Joanna Kamińska, Anna Milewska, Karol Sawicki, Marek Jadeszko, Zenon Mariak, Joanna Reszeć, Violetta Dymicka-Piekarska, Joanna Matowicka-Karna

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Olga M Koper-LenkiewiczDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland. o.koper@wp.pl.ORCID http://orcid.org/0000-0001-5199-2773
Joanna KamińskaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland.
Anna MilewskaDepartment of Statistics and Medical Informatics, Medical University of Bialystok, ul. Szpitalna 37, 15-295, Białystok, Poland.
Karol SawickiDepartment of Neurosurgery, Medical University of Bialystok, ul. M. Skłodowskiej-Curie 24a, 15-276, Białystok, Poland.
Marek JadeszkoDepartment of Neurosurgery, Medical University of Bialystok, ul. M. Skłodowskiej-Curie 24a, 15-276, Białystok, Poland.
Zenon MariakDepartment of Neurosurgery, Medical University of Bialystok, ul. M. Skłodowskiej-Curie 24a, 15-276, Białystok, Poland.
Joanna ReszećDepartment of Medical Pathomorphology, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Białystok, Poland.
Violetta Dymicka-PiekarskaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland.
Joanna Matowicka-KarnaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the previously suggested role of Neudesin in tumorigenesis and its potential as a novel target for the treatment of cancers, its prognostic value has never been examined. Thus, the aim of the study was to evaluate Neudesin concentrations in primary brain tumor patients and make a comparison with non-tumoral individuals.

methodsCerebrospinal fluid (CSF) and serum Neudesin concentration was evaluated by means of the ELISA method.

resultsThe total group of brain tumor patients had statistically lower serum Neudesin concentrations compared to the non-tumoral group (P = 0.037). The meningeal tumor subgroup also had statistically lower serum Neudesin concentrations compared to the non-tumoral group (P = 0.012). The Astrocytic brain tumor subgroup had significantly higher CSF Neudesin concentrations compared to the non-tumoral group (P = 0.046). Neudesin Quotient (CSF concentration divided by serum concentration) in the astrocytic brain tumor subgroup was statistically higher compared to the non-tumoral group (P = 0.023). Males had statistically lower concentrations of the serum Neudesin compared to females (P = 0.047). Univariate linear regression analysis revealed that for women the serum Neudesin concentration was 1.53 times higher than for men. In the model of multivariate linear regression analysis, predictor variables influencing serum Neudesin concentrations included CSF Neudesin concentration and the Neudesin Quotient, if other model parameters are fixed. The developed model explains 82% of the variance in serum Neudesin concentration. Both linear regression models, univariate and multivariate, pointed to fewer factors with a potential to influence the Neudesin Quotient compared to serum Neudesin concentration.

conclusionsIn astrocytic brain tumor patients Neudesin concentrations within the cerebrospinal fluid are higher compared with non-tumoral individuals. Serum Neudesin concentration strongly correlates with its CSF level. In primary brain tumor patients serum Neudesin concentration is clearly gender-dependent. Linear regression models pointed to fewer factors that may influence the Neudesin Quotient value, which suggests it is a better biomarker of astrocytic brain tumors than serum and CSF Neudesin concentrations alone.

Indexed as

Models, BiologicalAdultAgedAstrocytomaBiomarkers, TumorBrain NeoplasmsCase-Control StudiesFemaleHumansIntercellular Signaling Peptides and ProteinsLinear ModelsMaleMiddle AgedNerve Tissue ProteinsPredictive Value of TestsSex FactorsBiomarkers, TumorIntercellular Signaling Peptides and ProteinsNENF protein, humanNerve Tissue ProteinsBiomarkerCerebrospinal fluidNeudesinPrimary brain tumor

Identifiers

PMID30953468
PMCPMC6451205
OpenAlexW2941337216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.